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http:WHAT THIS PAPER ADDS
There are conﬂicting data on the relevance of centre versus single-practitioner experience on the results with
carotid stenting (CAS). This study would suggest that an effective team-working approach could signiﬁcantly
affect the performance of new trainees with CAS allowing improved outcomes and patients’ safety.Background: Operator training is a key factor for the safety of carotid stenting (CAS). Whether institutional
practice is associated with improved individual operator outcomes is debated.
Objective: To evaluate the effect of the institutional experience on outcomes of new trainees with CAS,
a retrospective analysis of a prospectively held database was performed.
Methods: The overall study period, 2004e2012, was divided into two sequential time frames: 2004eApril 2006
(leaders-team phase) and May 2006e2012 (expanded team phase). In the ﬁrst frame, a single leader-operators
team that ﬁrst approached CAS and passed the original institutional learning curve, performed all the procedures;
in the following expanded-team phase, ﬁve new trainees joined. Institutional CAS training for new trainees was
based on a team-working approach including selection of patients, devices and techniques and collegial meetings
with critical review and discussion of all procedural steps and imaging.
Results: A total of 431 CAS procedures were performed in the leaders-team phase and 1026 in the sequential
expanded-team phase. Periprocedural complication rates in the two time frames were similar: stroke/death
(3.0% vs. 2.1%; P ¼ 0.35), stroke (2.8% vs. 2.1%; P ¼ 0.45) major stroke (0.9% vs. 0.6%, P ¼ 0.49), death (0.2% vs.
0%; P ¼ 0.29) during the leaders-team and expanded-team phase, respectively. However, rates of CAS failure
requiring surgical conversions (3.7% vs. 0.8%; P < 0.0001) and mean contrast use (91.6 vs. 71.1 ml; P ¼ 0.0001)
decreased in the expanded phase. In the expanded-team frame (May 2006e2012), there was no mortality, and
stroke rates were comparable between the leader and new operator teams: 2.6% vs. 1.2%; P ¼ 0.17.
Conclusions: Institutional experience, including instruction on selection of patients and materials best suited for
the procedure, is a primary factor driving outcomes of CAS. An effective team-working approach can reliably
improve the training of new trainees preserving CAS safety and efﬁcacy.
 2013 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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and studies have demonstrated a substantial learning curve
with it.1,2 The worse outcome from CAS when compared to
carotid endarterectomy (CEA) recorded in multiple Euro-
pean randomised clinical trials (RCTs) has been in large part
explained by the lack of adequate training with the endo-
vascular procedure. International recommendations suggest
minimum volume requirements and training criteria for
potential CAS operators although with great variability
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//dx.doi.org/10.1016/j.ejvs.2013.02.003indicate that individual physician volume has an impact on
patient outcome from CAS.2,9e11 However, few studies have
evaluated the effect of the institutional training on the
single operator outcomes with CAS. The objective of this
study was to analyse whether institutional experience and
an effective institutional team working approach with CAS
may provide appropriate technical training, proﬁciency and
safe performance for new operators in a large-volume
centre.METHODS
Patients entered in a prospectively compiled computerised
database of carotid procedures performed at a single
vascular surgical centre were retrospectively analysed.
Procedures were applied by multidisciplinary operative
teams including vascular surgeons and interventional
Figure 2. Institutional carotid volume by year.
G. Parlani et al. 425radiologists. The ﬁrst 195 CAS procedures, reﬂecting the ﬁrst
approach to CAS at our centre performed from 2001 to
2003, represented the initial ‘learning curve’ phase of the
institution. It was after this training that the rate of CAS-
related major strokes (mainly occurring during the cathe-
terisation and ﬁlter time frames of CAS) signiﬁcantly
decreased to <2% per year.1 Thereby, this major stroke rate
was assumed to deﬁne an ‘experienced’ operator. The
operators who passed this learning curve frame were
deﬁned as the leader-operators team. From 2004 to April
2006, this team continued to perform all CAS. Subsequently,
from May 2006 to 2012, the operative team expanded with
ﬁve new trainees who joined and were denoted the ‘new-
operators’ team. Results of the learning curve period have
been previously published.1 This study focussed on the
following period 2004e2012 that was divided into two time
frames: the leaders team frame (2004eApril 2006) and the
expanded team frame (May 2006e2012) when ﬁve new
operators joined the leader-operators team (Fig. 1).
Over the study period, the Institutional CAS protocol was
progressively reﬁned including the lessons learnt with
increasing experience. Accordingly, the case mix selection
was based on physician-guided indications of best suitability
for CAS accounting for overall periprocedural risk evaluation
and presence of co-morbidities. Patients with >80 years,
unfavourable aortic arch anatomy, unstable ‘complex’
carotid plaque especially if recently symptomatic, severe
peripheral vascular disease precluding femoral access or
extremely tortuous carotid anatomy were progressively
excluded from CAS. Similarly, known allergies to aspirin,
clopidogrel or contrast media and renal insufﬁciency were
considered exclusion criteria for CAS.
With increasing experience and reﬁned patient selection,
the institutional CAS procedure expanded from the treat-
ment of only patients at high risk for CEA to the treatment
of common risk patients with carotid disease. Nevertheless,
after publication of multiple European trials questioning the
safety of CAS versus CEA,12e14 the institutional indications
for CAS in symptomatic patients became more limited, as
shown in Fig. 2.Figure 1. Study time frames and distribution of leader and new
operators.To evaluate the overall effect of the institutional training
on CAS results, patients’ case mix, technical details and
rates of complications between the leader team frame
(2004 to April 2006) and the sequential expanded team
frame (May 2006e2012) were compared. To assess the
efﬁcacy of the institutional team working on the new
operators (who did not actively participate in the original
institutional learning curve phase in 2001e2003), results
between the leader-operators team and the new-operators
team during the same expanded team phase (May2006e
2012) were compared.Institutional training for new trainees
Before performing CAS independently, new operators had
interacted with leader operators as observers and were
occasionally proctored during the procedures. The team-
working approach included routine institutional meetings
that involved leader operators and new trainees with critical
review and discussion of each CAS procedure regarding
whole intraprocedural imaging and technical steps and
selection of patients, materials, techniques and medications.
No simulator technology was used for technical training.Outcome measures
The primary ‘end’ point was the combined risk of any stroke
or death within 30 days (perioperative). Secondary ‘end’
points were each component of the primary ‘end’ point
(stroke and death), major stroke occurring within 30 days
after the procedure, procedure time, technical failure
(inability to complete the procedure without residual
stenosis >50%), contrast use, radiation exposure and
conversion to open procedure.Patient evaluation
Features and time of preoperative symptoms were evaluated
by external neurological audit. Patients were deﬁned as
symptomatic when ipsilateral hemispheric or retinal symp-
toms occurred within 6months prior to the procedure. Stroke
was deﬁned as any new hemispheric or retinal neurological
event persisting >24 h and classiﬁed as major (modiﬁed
Rankin Score 3) or minor (modiﬁed Rankin Score <3).
The degree and characteristics of carotid stenosis were
assessed with Duplex ultrasound.15
Figure 3. Carotid stenting volume by year and by operators team
(on the top of column total numbers).
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revascularisation.
In the case of neurological symptoms or uncertainty
occurring anytime during or after the procedure, the patients
were evaluated by a certiﬁed independent neurologist expert
in vascular diseases. Outpatient clinical and ultrasound
examinations were scheduled at regular intervals (6, 12
months and yearly thereafter).
CAS procedure
Patients received aspirin (125e325 mg once daily) and
clopidogrel (75 mg once daily after eventual 300 mg loading
dose) or ticlopidine (250 mg twice daily) before the
procedure. Patients under anticoagulation for co-existing
medical co-morbidities continued to receive their baseline
therapy. CAS was carried out in an endovascular room
equipped with a high-quality ﬁxed imaging system. Proce-
dures were performed through transfemoral or trans-
brachial approaches under local anaesthesia with minimal
or no sedation and the patients’ neurological status was
continuously monitored. Intravenous heparin (100 U kg1)
was routinely given before selective catheterisation of the
common carotid artery (CCA) and was not reversed at the
end of the procedure.With increased experience, diagnostic
aortic arch angiography was very selectively used, but
complete intracerebral vessel assessment was routinely
performed before and after the procedure. Various types of
cerebral protection devices (CPDs) and carotid stents (open
cell; closed cell or hybrid conﬁguration; tapered or straight)
were employed. The choice of speciﬁc material depended
on vessel anatomy and lesion characteristics and was
progressively reﬁned over the study period after critical
analysis of performed cases. Close cell stents were generally
used in straight vessels and in the presence of soft plaque.
There was a preference for using a ﬁlter as cerebral
protection. The reference carotid vessel diameter was
determined according to preoperative ultrasound
measurements. After stent deployment, completion angi-
ography was performed. Closure devices were used for
access site control since 2006.
Postprocedure anti-platelet therapy included dual drug
treatment (aspirin and thienopyridines) for a minimum of 1
month and continued at the treating physicians’ discretion.
Statistical analysis
Descriptive statistics were used to evaluate differences in
baseline characteristics, indications for treatment and tech-
nical details between the leaders-team phase (2004eApril
2006) and the expanded-team phase (May 2006e2012). The
incidence of 30-day stroke or death and secondary outcomes
was compared between the two time frames.
During the expanded team phase, 30-day outcomes were
also compared between procedures performed by the new-
operators team and the leader-operators team.
Multivariate logistic regression analysis was employed to
assess the relationship between the incidence of 30-day
stroke or death and the team phase adjusted for age,gender, symptomatic condition, co-morbidities (coronary
disease, peripheral disease and diabetes) use of statins and
stent type (close vs. open design) using backward stepwise
selection of variables to be tested.
Results were reported as odds ratio (OR), adjusted OR
and their corresponding 95% conﬁdence intervals (CIs). All
analyses were performed using Statistical Package for the
Social Sciences (SPSS) PC version 13.00 Win package (SPSS
for Windows Chicago, IL, USA, 2003).
P < 0.05 was considered statistically signiﬁcant and all
tests were two-sided.RESULTS
Study cohort
A total of 1457 CAS procedures performed since January
2004 to March 2012 were reviewed. Mean age of patients
was 71.7  7.5 years; 441 (30%) were females. A total of
431 procedures were performed in the leader-team phase
(2004eApril 2006) and 1026 in the expanded-team phase
(May 2006e2012). Volumes of carotid procedures and
operator team distribution by year are shown in Figs. 2 and
3. The CAS volume per year over the expanded phase
decreased: n ¼ 184 CAS were performed in 2006 (Maye
December), n ¼ 244 in 2007, n ¼ 226 in 2008, n ¼ 135 in
2009, n ¼ 85 in 2010 and n ¼ 107 in 2011. In the ﬁrst 3
months of the last year (2012), an additional 45 CAS
procedures were performed (Fig. 3).Outcomes in leaders team (2004eApril 2006) versus
expanded team (May 2006eMarch 2012) frames
Distribution of demographic, co-morbidities and intra-
procedural materials between the leaders team and the
expanded team phases are shown in Table 1.
Compared to CAS performed in the expanded team phase,
patients treated in the leaders team phase were about 1 year
older (P ¼ 0.04) and were more likely to show peripheral
Table 1. Comparison of the “leader team phase” (2004e2006) and the sequential “expanded team phase” (2006e2012). Demographic,
comorbidities, indications for treatment, technical details and complications.
Patients characteristics Leaders team phase
(2004e2006) CAS ¼ 431
Expanded team phase
(2006e2012) CAS ¼ 1026
OR 95%CI P_value
N (%) N (%)
Age, years,mean  SD 72.3  7.5 71.4  7.5 0.43 0.04
Males 307 (71.4) 709 (69.2) 0.89 0.70e1.15 0.41
Symptomatic 70 (16.3) 208 (20.3) 1.31 0.97e1.76 0.08
Coronary disease 202 (47.0) 309 (30.1) 0.49 0.39e0.61 0.0001
Peripheral artery disease 71 (16.5) 123 (12.0) 0.69 0.50e0.95 0.02
Diabetes 135 (31.4) 319 (31.1) 0.99 0.77e1.26 0.95
Hypertension 384 (89.3) 832 (81.1) 0.51 0.36e0.72 0.0001
Statins 160 (37.2) 575 (56.1) 2.16 1.71e2.72 0.0001
Contralateral occlusion 35 (8.1) 77 (7.5) 0.98 0.96e1.02 0.66
Previous CEA (restenosis) 13 (3.1) 52 (5.1) 0.58 0.31e1.08 0.09
Bilateral procedure 37 (8.6) 85 (8.3) 0.96 0.64e1.43 0.83
Technical details:
Close cell stent 257 (59.6) 761 (74.2) 1.94 1.52e2.46 0.0001
Operation time, mean,
min  SD
52.3  17.1 50.7  16.1 0.16
Contrast per procedure,
mean, mL  SD
91.66  25.6 71.11  23.5 0.0001
Radiation time, mean,
min  SD
14.13  6.4 12.93  6.4 0.002
Intraprocedural details:
Technical failure 16 (3.7) 5 (0.5) 0.97 0.95e0.98 <0.0001
Conversion to CEA 16 (3.7) 8 (0.8)a 0.20 0.08e0.48 <0.0001
Periprocedural outcome:
Any stroke or death 13 (3.0) 22 (2.1) 0.70 0.35e1.41 0.35
Any stroke 12(2.8) 22 (2.1) 0.76 0.37e1.56 0.45
Major stroke 4 (0.9) 6 (0.6) 0.63 0.18e2.23 0.49
Death 1 (0.2) 0
CAS: Carotid stenting; CEA: carotid endarterectomy.
a Three early stent thrombosis after technical successful procedure.
G. Parlani et al. 427disease (P ¼ 0.02), coronary disease (P < 0.0001) and
hypertension (P< 0.0001). Use of statins was more common
in the expanded phase (56.1% vs. 37.2%; P < 0.0001).
The overall perioperative (30-day) stroke or death rate for
the 2004e2012 period was 2.4% (35/1457) and was similar
in the leaders-team phase (3.0%) and in the expanded-team
phase (2.1%): OR 0.70, 95%CI0.35e1.41, P ¼ 0.35. Rates of
perioperative stroke were 2.8% versus 2.1% (P ¼ 0.45), of
major stroke were 0.9% versus 0.6% (P ¼ 0.49) and of
perioperative mortality were 0.2% versus 0% (P ¼ 0.29) in
the two phases, respectively. Mean duration of operation
was similar in the two phases, but mean contrast use and
radiation time were decreased in the expanded phase
(Table 1). The rate of immediate conversion to CEA
(including those performed for early stent thrombosis after
successful procedure) was higher in the leader-team phase:
3.7% versus 0.8%, P ¼ 0.0001 (Table 1).Outcomes in the expanded team phase (May 2004e2012):
leaders team versus new operators team
In the expanded team phase (May 2006eMarch 2012),
1026 CAS procedures were performed: 683 by the leader
operators and 343 by the new operators (Fig. 1). The CAS
volume ratio for new operators team increased in the lastyears and represented 9.2% in 2006 (MayeDecember),
9.8% in 2007, 24.8% in 2008, 42.2% in 2009, 81.0% in 2010
and 77.4% in 2011 of the overall CAS volume (Fig. 3).
Perioperative stroke or death rate during the expanded
team phase was similar for the two teams: 2.6% in the 683
procedures performed by the leader-operators team and
1.2% in the 343 procedures performed by the new-operators
team (OR 0.44, 95%CI 0.15e1.3, P ¼ 0.17). There was no
perioperative mortality, while perioperative stroke and
major stroke rates were comparable (Table 2). Details on
outcomes achieved by the ﬁve new operators are shown in
Table 3. No major strokes or deaths occurred for procedures
performed by each new trainee as ﬁrst operator. Thereby, all
the new operators could be deﬁned as ‘experienced’
(according to the 2% major stroke threshold established in
the learning curve frame, see Methods section). However,
CAS volume per each of the ﬁve new independent operators
varied, ranging from 12 to 214, as detailed in Table 3.
Overall, no complications occurred for three new trainees
while four minor strokes were recorded for two of the ﬁve
new-operators: two among CAS procedures performed by
the new operator #1 with the largest experience (214) and
accounting for 0.9% of his overall performance and two
among the 35 CAS procedures of the new operator #3
(accounting for 5.7% of his records). Stroke rates of the
Table 2. Expanded team phase (2006e2012). Periprocedural outcomes for the leader-operators team and the new-operators team.
Leader-operators
team CAS ¼ 683
New-operators
team CAS ¼ 343
OR 95%CI P_value
N (%) N (%)
Periprocedural outcomes
Any stroke or death 18 (2.6) 4 (1.2) 0.44 0.15e1.30 0.17
Any stroke 18 (2.6) 4 (1.2) 0.44 0.15e1.30 0.17
Major stroke 6 (0.9) 0 0.99 0.98e0.99 0.18
Death 0 0 e e e
Intraprocedural details
Technical failure 3 (0.4) 2 (0.6) 0.7 0.12e4.51 0.99
Conversion to CEA 5 (0.7)a 3 (0.9)b 1.2 0.28e5.05 0.99
CAS: Carotid stenting; CEA: carotid endarterectomy.
a Two early stent thrombosis after technical successful procedure.
b One early stent thrombosis after technical successful procedure.
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cantly increased when compared to that of the leader-
operators team: OR 2.17, P ¼ 0.62 for operator #5 and OR
0.35, P ¼ 0.16 for operator #1. Similarly, there was no
signiﬁcant difference in the stroke rate of the new operator
with the largest number of performances and that of the
other new operator with the worst outcome (#1 vs. #5),
Table 3.
Due to the large variability of volume among the new
operators, the effect of timing on periprocedural risk was
analysed: perioperative stroke/death rate was investigated
for the ﬁrst 15 CAS procedures versus later procedures.
There were no strokes in the ﬁrst 15 CAS procedures for
each new operator regardless of the total number of
procedures performed.
Furthermore, in the expanded phase 2006e2012, peri-
operative stroke or death rates were comparable between
the two teams (leader vs. new-operators) in analyses
stratiﬁed by preoperative symptoms. For 208 CAS proce-
dures performed in symptomatic patients, stroke rates were
0% (0/51) versus 3.0% (5/157; P ¼ 0.34) and major stroke
rates 0% versus 1.9% (3/157; P ¼ 0.99) in the new-
operators and the leader-operators team, respectively. For
818 procedures in asymptomatic patients, stroke rates were
1.4% (4/292) versus 2.5% (13/526; P ¼ 0.44) and major
stroke rates were 0% versus 0.6% (3/526) P ¼ 0.56 in the
two teams, respectively.
Multivariate analysis with backward selection of
confounders failed to show any signiﬁcant relationshipTable 3. New operators details during “expanded team phase” 2006e
Individual
CAS volume
30-day
stroke/death
Compariso
leader tea
N N (%) OR 95%CI
#1 New operator 214 2 (0.9%)* 0.35 (0.08
P ¼ 0.18
#2 New operator 47 0
#3 New operator 33 2 (5.7%)* 2.17(0.48e
P ¼ 0.62
#4 New operator 12 0 0
#5 New operator 35 0 0
CAS: Carotid stenting; OR: Odds ratio; 95%CI: 95% Conﬁdence Interva
*Operator #1 vs. Operator #5: OR 0.16, 95%CI 0.022e1.199; P ¼ 0.10between the new-operator team and increased primary
outcome (OR 0.53; 95%CI 0.17e1.62;P ¼ 0.27). The only
independent association with decreased 30-day stroke/
death risk was statins use (OR 0.36; 95%CI 0.14e0.88;
P ¼ 0.026).
DISCUSSION
CAS is technically challenging and the existence of
a consistent operator learning curve has been required.1e
3,7e9 However, in a large-volume centre with a proper
training programme, institutional experience more than
single operator proﬁciency is a major factor in driving per-
iprocedural stroke/mortality risk during a CAS procedure. In
this study, a similar low periprocedural risk of stroke (2.6%
vs. 1.2%), death (0% vs. 0%) and major stroke (0.9% vs. 0%)
was achieved in CAS procedures performed by the leader-
operators team (old team) and the new-operators team
who started performing CAS independently after the insti-
tutional learning curve and indirectly assimilated the
training experience. New operators can take advantage of
the effective team-working approach and obtain similar
good outcomes with CAS.
A number of studies focussed on volume as a marker of
quality and a surrogate for outcome in surgical and endo-
vascular procedures, without uniform conclusions.9e11,16e21
Some authors suggested that results from CAS are affected
by the single operator more than by the institutional
experience. Nevertheless, there is no consensus on the
number of CAS procedures required to deﬁne the safety of2012.
n with
m (rate 2.6%)
30-day major
stroke/death
30-day stroke/death
in the ﬁrst 15 procedures
N (%) N (%)
e1.54) 0 0
0 0 0
9.71) 0 0
0 0
0 0
ls.
.
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providers are largely variable and remains unsettled by
current guidelines.3e6 According to the SIENA score,9 in
over 2124 CAS procedures performed in 2000e2009 at
a single centre, the operator’s experience of >100 CAS
procedures was the only protective factor against the
development of stroke at 30 days (OR 0.81; 95%CI 0.67e
0.95).9 Vogel et al. analysed 18,599 CAS procedures per-
formed in the USA in the years 2005e2006 based on
Nationwide Inpatient Sample (NIS).11 Stroke rate after CAS
was signiﬁcantly different between low- and high-volume
(>60 CAS/year) hospitals (2.35% vs. 1.78%, P ¼ 0.02) but
also between low- and high-volume (>30 CAS/2 years)
practitioners (2.19% vs. 1.51%; P ¼ 0.02).11 Similar
suggestions were provided recently by Nallamothu et al.
using administrative data of 24,701 CAS procedures per-
formed by 2339 US operators (years 2005e2007) but with
different volume thresholds and using mortality (not stroke)
as ‘end’ point.2 Accordingly, 30-day mortality after CAS was
higher among patients treated by operators with lower
annual volume ranging from 2.5% for those with <6 CAS to
1.4% for those with >24 CAS experience (P < 0.001).
Nevertheless, the latter studies2,11 were based on admin-
istrative codes and accuracy may be limited; furthermore,
data were gathered from procedures performed prior to
2008 and, hopefully, CAS practice has improved over the
more recent 5 years.
Establishing a precise operator volume to assess the
experience in performing CAS is challenging to be stand-
ardised in training formal protocols. Besides numbers, many
other factors can positively or oppositely affect outcomes of
CAS providers with comparable volume. In large-volume
centres optimal institutional training for safe CAS involves
not only technical tutoring but also instruction on patient,
device and imaging selection. Institutional experience
incorporates multiple minor technical improvements,
progressive materials and medical therapy evolutions,
accurate procedural planning, case-mix selection and
lessons learnt from systematic collegial critical review step
by step of all cases (including the whole procedural imaging)
that can be similarly incorporated by old operators and new
trainees leading to the achievement of comparable and safe
outcomes. Not all the progressive changes and technical
improvements can be standardised and incorporated in
formal training statements as these are often subtle and
strictly related to the individual patient complexity: an
effective team working can be more instructive in this
regard.
Beyond technical skill, indication for treatment, case mix
and resource utilisation (materials selection) are essential
factors in driving stroke/death risk for CAS. There is a rela-
tionship between patient selection and CAS outcomes:
young patients with appropriate anatomy (absence of
excessive vessel tortuosity or diffuse arch or common
carotid disease) are optimal candidates for the procedure.
In this study, there was substantial overlap between the
leader-operators team and the new-operators team in
results that can be affected by the shared criteria fortreatment between the two teams including improvements
in medical therapy and general patient management
progressively incorporated in the institutional practice by
both, old and new trainees. The beneﬁt of statins during
CAS was supported by recent literature results and also by
the systematic critical internal review of our institutional
data.22,23
We found that procedural risk between new- and leader-
operators was similar when restricted to patients with
symptomatic carotid disease: stroke rates 0% versus 3.0%
(5/157; P ¼ 0.34) and major stroke rates 0% versus 1.9% (3/
157; P ¼ 0.99), in the new-operators and the leader-
operators team, respectively. However, due to the smaller
subgroups these analyses should be interpreted with
caution.
Vogel et al. correlated volume and resource utilisation
during CAS and found a signiﬁcant difference in resource
utilisation with increased length of stay and total charges
for low volume versus High-volume CAS practitioners.10,11
In this study costs for procedures were not analysed; the
effective institutional training and evolving technology
available for our new operators should have avoided
excessive costs.Study limitations
Limitations of the study include the retrospective analysis
and the single centre experience allowing limited general-
isation of the results. However, we believe that our ﬁndings
may be extended to other large-volume centres if a proper
training (team working approach) is applied. Another limi-
tation is the various procedure volumes for each operator
with limited numbers for most of them. Case selection and,
speciﬁcally, the small number of symptomatic patients
might have inﬂuenced the overall good outcome achieved.
Finally, analysis of costs related to facility utilisation was
outside the scope of this study.CONCLUSIONS
Operator volume to establish experience with CAS is chal-
lenging to be standardised in formal training programmes
and remains unsettled in common practice. In centres with
effective training and large-volume expertise, CAS compli-
cation rates might be related to the institutional proﬁciency
encompassing also procedures performed by new trainees.
Institutional experience is built on progressive improvement
over time in technique, patient’s selection, device selection
and adjunctive medical management, along with the
lessons learnt from routine collegial review of all proce-
dures and related imaging. An optimal institutional CAS
team working can reliably improve the learning curve of
new trainees preserving procedural efﬁcacy and patient
safety.FUNDING
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